Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis
Tao Jiang(Tongji University), Caicun Zhou(Tongji University), Fei Zhou(Tongji University), Shengxiang Ren(Tongji University), Yan Wang(Shanghai Pulmonary Hospital), Guanghui Gao(Tongji University)
Cited by 66
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504